ResultsIQ

ResultsIQ › Latest results › Gufic Biosciences Limited

Gufic Biosciences Limited Q2 FY27 results deck summary

NSE: GUFICBIO · BSE: 509079

Results deck of 14 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹288.4 cr and PAT ₹23.5 cr, as Indore's US FDA inspection closed with three observations being addressed.

Key takeaways

  1. Q2 FY27 result Total revenue ₹288.4 cr and PAT ₹23.5 cr, with EBITDA ₹49.7 cr at 17.23% margin.
  2. Margin change EBITDA margin at 17.23% is below Q1 FY27's 18.10% but above Q2 FY26's 16.45%.
  3. Growth driver International registrations converted into first orders in the Gulf and Latin America, with Gufic Ireland widening European distribution.
  4. Main risk Indore's US FDA pre-approval inspection closed with three observations still being addressed.

Original filing on BSE

Gufic Biosciences Limited Q2 FY27 results

As filed: Revenue ₹288 cr (+22% year on year), EBITDA ₹48.5 cr (+24% year on year), PAT ₹23.5 cr (+38% year on year), EBITDA margin 16.8% (+37 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹261 cr (+16% year on year), EBITDA ₹46.6 cr (+41% year on year), PAT ₹22.3 cr (+72% year on year), EBITDA margin 17.9% (+314 bps). Score 77 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 314 bps year on year. Revenue rose ₹36.8 cr on a year ago, more than the ₹21.0 cr it added the year before. Share price after the results: +0.7% in 28 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹252 cr (+23% year on year), EBITDA ₹47.2 cr (+75% year on year), PAT ₹21.9 cr (+174% year on year), EBITDA margin 18.8% (+558 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 558 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +8.3% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹231 cr (+11% year on year), EBITDA ₹33.0 cr (−3% year on year), PAT ₹12.4 cr (−35% year on year), EBITDA margin 14.3% (−209 bps). Score 46 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 209 bps year on year. Profit fell 27% from last quarter. Share price after the results: −7.1% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹237 cr (+16% year on year), EBITDA ₹39.0 cr (+3% year on year), PAT ₹17.0 cr (−23% year on year), EBITDA margin 16.5% (−217 bps). Score 60 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin fell 217 bps year on year. Share price after the results: +9.4% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹224 cr (+10% year on year), EBITDA ₹33.0 cr (−8% year on year), PAT ₹13.0 cr (−38% year on year), EBITDA margin 14.7% (−300 bps). Score 26 of 100, Below trend. EBITDA margin fell 300 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +3.5% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹205 cr (+5% year on year), EBITDA ₹27.0 cr (−21% year on year), PAT ₹8.0 cr (−60% year on year), EBITDA margin 13.2% (−427 bps). Score 17 of 100, Below trend. EBITDA margin fell 427 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 58% from last quarter. Share price after the results: −10.7% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹208 cr (+3% year on year), EBITDA ₹34.0 cr (−8% year on year), PAT ₹19.0 cr (−14% year on year), EBITDA margin 16.4% (−197 bps). Score 25 of 100, Below trend. EBITDA margin fell 197 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 14% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Gufic Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.